Patients with juvenile idiopathic arthritis achieved long-term disease control with subcutaneous tocilizumab treatment, without any new safety concerns, in an LTE study of two trials.
Longer tocilizumab administration intervals and lower prednisolone doses seemed pivotal for successful tocilizumab withdrawal while maintaining remission in patients with AOSD.
Advocate Health Care pediatric patient June Kenoe and her family joined the Chicago Bulls at the United Center Friday night for a special pregame experience before the Bulls took on the New York Knick.
Israel’s Teva Pharmaceuticals received approval from the Food and Drug Administration for the SIMLANDI (adalimumab-ryvk) injection, for the treatment of a number of different forms of arthritis, colitis and Chron’s Disease, among others. The drug is developed together with Iceland’s Alvotech and its marketing could lead to billions in sales. SIMLANDI is the first high-concentration, […]